LP
UTHR icon

LMR Partners’s United Therapeutics UTHR Stock Holding History

LMR Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-77,400
Closed -$32.4M – 1745
2025
Q3 		$32.4M Buy
+77,400
New +$26M 0.14% 115

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

LMR Partners's UTHR Position: Q2 2026 in Review

LMR Partners reduced its United Therapeutics (UTHR) stake by 76% in Q2 2026, selling an estimated $7.05M and leaving 3,911 shares worth $2.12M. The position accounts for 0.01% of the portfolio, ranked #882.

LMR Partners first reported a position in UTHR in Q1 2015 and has held it in 8 quarters since. The position peaked at $9.75M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • LMR Partners held 3,911 shares of United Therapeutics worth $2.12M as of Q2 2026.
  • LMR Partners sold 12,525 United Therapeutics shares in Q2 2026, an estimated $7.05M.
  • United Therapeutics made up 0.01% of LMR Partners's portfolio in Q2 2026, its #882 holding.
  • LMR Partners first reported a position in United Therapeutics in Q1 2015 and has held it in 8 quarters since.
  • LMR Partners's United Therapeutics position peaked at $9.75M in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.